EMBC

Embecta Corp
NASDAQHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES

Key Statistics

Market Cap
$196.67M
P/E Ratio
1.75
EPS
$1.89
Beta
0.81
52W High
$15.08
52W Low
$2.76
50-Day MA
$4.10
200-Day MA
$9.80
Dividend Yield
17.80%
Profit Margin
10.70%
Forward P/E
PEG Ratio

About Embecta Corp

Embecta Corp (EMBC) is a prominent medical technology company dedicated to innovating insulin delivery systems for diabetes management. Established as a spin-off from Becton, Dickinson and Company, Embecta offers a wide range of advanced products, including state-of-the-art insulin pens and syringes, designed to improve patient outcomes. With a strong commitment to operational excellence and customer satisfaction, Embecta is strategically poised to leverage growth opportunities in the expanding diabetes care market, thereby reinforcing its leadership role in this critical sector.

Official WebsiteUSAFY End: September

Fundamentals

Revenue (TTM)$1.04B
Gross Profit (TTM)$645.50M
EBITDA$332.30M
Operating Margin19.30%
Return on Equity0.00%
Return on Assets16.80%
Revenue/Share (TTM)$17.74
Book Value$-10.55
Price-to-Book2.61
Price-to-Sales (TTM)0.19
EV/Revenue1.316
EV/EBITDA4.40
Quarterly Earnings Growth (YoY)82.70%
Quarterly Revenue Growth (YoY)-14.40%
Shares Outstanding$59.33M
Float$58.33M
% Insiders1.74%
% Institutions100.37%

Historical Volatility

HV 10-Day
HV 20-Day
HV 30-Day
HV 60-Day
HV Rank

Analyst Ratings

Consensus ($4.00 target)
1
Buy
2
Hold
1
Strong Sell

Latest News

EMBC SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Embecta Investors of Securities Class Action Lawsuit Deadline on August 17, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Embecta To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Embecta between November 25, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 9, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC) and reminds investors of the August 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Newsfile Corp7/9/2026Neutral
EMBECTA CORP. (EMBC) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Embecta Corp. Investors of Upcoming Deadline

NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) investors of the  August 17, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Embecta Class Action Lawsuit : Do you, or did you, own shares of Embecta Corp. (NASDAQ: EMBC)?

GlobeNewsWire7/9/2026Neutral
EMBC Deadline Alert: SueWallSt Reminds Embecta Corp. (EMBC) Investors of Securities Class Action Deadline on August 17, 2026

Alert: Claims Focus on Alleged Misrepresentations About U.S. Pen Needle Revenue Stability as Embecta's Business Declined Over 14% NEW YORK, July 9, 2026 /PRNewswire/ -- SueWallSt reminds purchasers of Embecta Corp. (NASDAQ: EMBC) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased Embecta securities between November 25, 2025 and May 4, 2026.

PRNewsWire7/9/2026Neutral
EMBC INVESTOR DEADLINE: Embecta Corp. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit-- HBSS

SAN FRANCISCO, July 9, 2026 /PRNewswire/ -- Embecta Corp. (NASDAQ: EMBC) faces a securities class action lawsuit, which seeks to represent investors who purchased or acquired Embecta common stock between November 25, 2025 and May 4, 2026. The lawsuit follows the company's disastrous Q2 2026 earnings report, apparently at odds with prior narrative, which triggered a massive selloff in the stock and analysts' questions.

PRNewsWire7/9/2026Neutral
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit

NEW YORK, July 8, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 17, 2026 lead plaintiff deadline. So what: If you purchased Embecta common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

PRNewsWire7/8/2026Neutral
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Embecta Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EMBC

New York, New York--(Newsfile Corp. - July 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 17, 2026 lead plaintiff deadline. SO WHAT: If you purchased Embecta common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Newsfile Corp7/8/2026Neutral
Embecta Corp. (EMBC) Faces Securities Class Action for Allegedly Concealing Competitive Threats to Pen Needle Business -- HBSS

SAN FRANCISCO, July 08, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (NASDAQ: EMBC) faces a securities class action lawsuit, which seeks to represent investors who purchased or acquired Embecta common stock between November 25, 2025 and May 4, 2026. The lawsuit follows the company's disastrous Q2 2026 earnings report, apparently at odds with prior narrative, which triggered a massive selloff in the stock and analysts' questions.

GlobeNewsWire7/8/2026Neutral
Embecta Corp. (EMBC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES, July 8, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC). IF YOU SUFFERED A LOSS ON YOUR EMBECTA INVESTMENTS, CLICK  HERE BEFORE AUGUST 17, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?

PRNewsWire7/8/2026Neutral
Bronstein, Gewirtz & Grossman LLC Urges Embecta Corp. Investors to Act: Class Action Filed Alleging Investor Harm

New York, New York--(Newsfile Corp. - July 8, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Embecta securities between November 25, 2025 and May 4, 2026, both dates inclusive (the "Class Period").

Newsfile Corp7/8/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026